Loading...
Loading...
ERNA| Name | Value |
|---|---|
| Revenues | 47.0K |
| Cost of Revenue | 95.0K |
| Gross Profit | -48.0K |
| Operating Expense | 4,883.0K |
| Operating I/L | -4,931.0K |
| Other Income/Expense | -595.0K |
| Interest Income | 0.0K |
| Pretax | -5,526.0K |
| Income Tax Expense | 3.0K |
| Net Income/Loss | -5,529.0K |
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company specializing in developing innovative therapies for cancer treatment. Its primary focus is on the advancement of IRX-2, currently in a Phase 2b clinical trial for squamous cell cancer of the head and neck. Additionally, the company is leveraging gene-editing and cell therapy technology to develop treatments for oncology, blood disorders, and monogenic diseases.
